The overwhelming majority of cases occurred within a week of vaccination, Shimabukuro said.
VAERS data showed 283 cardiac inflammations observed in patients aged 16 to 24 years after the second vaccination. According to the CDC, this is compared to the forecast of 10 to 102 cases in that age group, based on the US population background incidence.
Shimabukuro said that among the reported cases of carditis, men in the younger age group predominate.
According to VAERS data, the median age of patients who experienced inflammation after the second vaccination was 24 years. A little less than 80% of the cases were male.
Shimabukuro also said that another safety monitoring system, Vaccine Safety Datalink (VSD), had a higher incidence of cardiac inflammation between the ages of 16 and 39 years after the second injection, compared to the rate observed after the first dose. He said it showed an increase.
Pfizer said it supported the evaluation of cases of heart inflammation by the CDC, saying that “the number of reports is small given the number of doses administered.”
About 130 million people in the United States I am receiving both doses of one of the mRNA vaccines.
“It is important to understand that careful evaluation of the report is underway and it has not been concluded that the mRNA COVID-19 vaccine causes myocarditis or pericarditis,” the company said in a statement. It was.
Moderna also said that he had not established a causal relationship between the condition and its vaccine. He said he is actively working with public health and regulators to further assess this issue.
The CDC said it will hold a meeting of the Immunization Implementation Advisory Committee next week to further evaluate post-mRNA vaccination evidence for COVID-19 and assess the risk of myocarditis.
Cases of cardiac inflammation in young men after Pfizer, Modana vaccine, CDC report
Source link Cases of cardiac inflammation in young men after Pfizer, Modana vaccine, CDC report